Biotech Company With Clinical Operations Developing Psychedelic Medicine To Treat Addiction

First 3 UK Clinics Opened In 2021, Targeting 20 Clinics By 2024 ~$100M In Revenue

Free
Discussion Forum: Awakn Life Sciences Corp.
List Message View
Thread Message View
New Message
Message Title
Rating
Author / Date
Icon agoracom Awakn Life Sciences Identifies New Chemical Series via Its Drug Discovery Program

AGORACOM-NR
Oct 28, 2021 07:30AM
Icon agoracom Awakn Life Sciences to Present at the Benzinga Global Small Cap Conference

AGORACOM-NR
Oct 22, 2021 09:00AM
Icon agoracom Awakn Life Sciences Bristol Clinic Receives Care Quality Commission Approval to Begin Treatments in the UK's First Medical Psychedelic Clinic

AGORACOM
Oct 20, 2021 07:30AM
Icon agoracom VIDEO - Awakn Life Sciences Corp. (AWKN: NEO) Clinic Roll-Out Addresses The Multi-Billion Dollar Addiction Treatment Industry With Psychedelics

AGORACOM
Oct 12, 2021 09:20AM
Icon agoracom Awakn Life Sciences to Present at the KCSA Psychedelics Virtual Investor Conference on October 13th

AGORACOM-NR
Oct 08, 2021 04:30PM
Icon agoracom Awakn Life Sciences Announces Closing of Acquisition of Leading Ketamine-Assisted Psychotherapy Clinic in Norway

AGORACOM-NR
Oct 05, 2021 07:30AM
Icon agoracom INTERVIEW ALERT: Awakn Life Sciences Corp., (AWKN: NEO) (AWKNF: OTCQB)

AGORACOM
Sep 29, 2021 12:16PM
Icon agoracom Awakn Life Sciences Acquires Exclusive Rights to MDMA Research from Imperial College London

AGORACOM-NR
Sep 23, 2021 08:01AM
Icon agoracom Awakn Life Sciences to Present at the Oppenheimer and Maxim Group September Investor Conferences

AGORACOM-NR
Sep 20, 2021 02:00PM
Icon agoracom Awakn Life Sciences to Acquire Leading Ketamine-Assisted Psychotherapy Clinic in Norway

AGORACOM-NR
Sep 16, 2021 07:53AM
Icon agoracom Awakn Life Sciences Reports Second Quarter 2021 Financial Results and Business Highlights

AGORACOM-NR
Sep 15, 2021 07:30AM
Icon agoracom Awakn Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

AGORACOM-NR
Sep 09, 2021 07:30AM
Icon agoracom Awakn Life Sciences Announces DTC Eligibility

AGORACOM-NR
Sep 02, 2021 07:30AM
Icon agoracom Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor Celia Morgan

AGORACOM-NR
Aug 24, 2021 07:30AM
Icon agoracom Awakn Life Sciences to Present at the Canaccord Genuity 41st Annual Virtual Growth Conference

AGORACOM-NR
Aug 09, 2021 10:07AM
Icon agoracom Awakn Life Sciences Announces Its Second Location in the UK for "Awakn Clinics London", Providing Treatment to the Largest City in the UK

AGORACOM-NR
Aug 04, 2021 10:06AM
Icon agoracom Awakn Life Sciences to Commence Trading on the OTC Market on July 26, 2021 Under the Symbol 'AWKNF'

AGORACOM-NR
Jul 26, 2021 08:15AM
Icon agoracom Awakn Life Sciences Initiates Research Program to Further Develop Ketamine-Assisted Therapies for Treating Addiction

AGORACOM-NR
Jul 14, 2021 07:30AM
Icon agoracom Awakn Establishes Separate Preclinical and Clinical Expert Advisory Boards to Optimize Delivery of Its Expanding Development Pipeline

AGORACOM-NR
Jul 07, 2021 08:15AM
Icon agoracom Awakn Life Sciences Files Patent Applications in U.S. for AWKN001 and AWKN002, Two Next-Generation New Chemical Entities...

AGORACOM-NR
Jun 28, 2021 07:30AM
New Message